Literature DB >> 26279841

IBD-related work disability in the community: Prevalence, severity and predictive factors. A cross-sectional study.

Alexis Ramos1, Xavier Calvet2, Beatriz Sicilia1, Mercedes Vergara2, Ariadna Figuerola2, Jaume Motos3, Adoración Sastre1, Albert Villoria2, Fernando Gomollón4.   

Abstract

BACKGROUND AND AIMS: Data on the prevalence of work disability in patients with inflammatory bowel disease (IBD) are heterogeneous. As most studies have been performed in selected, often severe, IBD patients, the true prevalence of disability in the community remains controversial. The aim of this cross-sectional study was to evaluate the prevalence and severity of disability and its predictive factors in a community-based IBD population. PATIENTS AND METHODS: Patients recorded in the community-based IBD register at the Hospital Universitario de Burgos were contacted. After informed consent they completed a set of questionnaires including demographic, clinical, disability and quality of life data. The statistical study was performed using SPSS 21.
RESULTS: A total of 293 patients were included - 151 Crohn's disease (CD), 142 ulcerative colitis (UC), 137 female, mean age: 45 ± 11 years, mean time since diagnosis: 10.6 ± 11 years. Twelve patients (4.1%) had a work-disability pension. In addition, 93 (32%) of all patients had an officially recognized disability degree, which was generally moderate (n = 73, 25%) or severe (N = 16, 5%). Age, time since IBD diagnosis, CD, perianal disease, incontinence, active disease, the need for anti-TNF or psychological treatment, previous surgeries and the number of diagnostic tests and medical visits in the previous year were predictors of disability. Major predictors of qualifying for a disability pension were age, IBD activity, incontinence, need for biological drugs and ostomy.
CONCLUSION: Mild to moderate work disability is frequent in IBD. However, only a minority of patients develop severe disability qualifying them for a pension.

Entities:  

Keywords:  Crohn's disease; Disability; inflammatory bowel disease; ulcerative colitis

Year:  2015        PMID: 26279841      PMCID: PMC4528207          DOI: 10.1177/2050640615577532

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  30 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Disability and need for rehabilitation among patients with inflammatory bowel disease.

Authors:  A Sonnenberg
Journal:  Digestion       Date:  1992       Impact factor: 3.216

3.  US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

Authors:  James W Shaw; Jeffrey A Johnson; Stephen Joel Coons
Journal:  Med Care       Date:  2005-03       Impact factor: 2.983

4.  Unemployment and disability in patients with moderately to severely active Crohn's disease.

Authors:  Brian G Feagan; Mohan Bala; Songkai Yan; Allan Olson; Stephen Hanauer
Journal:  J Clin Gastroenterol       Date:  2005 May-Jun       Impact factor: 3.062

5.  Disability in IBD: the devil is in the details.

Authors:  Joseph Sellin
Journal:  Inflamm Bowel Dis       Date:  2010-01       Impact factor: 5.325

6.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

7.  Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.

Authors:  James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg
Journal:  Inflamm Bowel Dis       Date:  2008-12       Impact factor: 5.325

Review 8.  Sick leave and disability pension in inflammatory bowel disease: a systematic review.

Authors:  Katharina Büsch; Simone A da Silva; Michelle Holton; Fabiana M Rabacow; Hamed Khalili; Jonas F Ludvigsson
Journal:  J Crohns Colitis       Date:  2014-07-04       Impact factor: 9.071

9.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

Authors: 
Journal:  J Am Coll Dent       Date:  2014

10.  STrengthening the Reporting of OBservational studies in Epidemiology--Molecular Epidemiology (STROBE-ME): an extension of the STROBE Statement.

Authors:  Valentina Gallo; Matthias Egger; Valerie McCormack; Peter B Farmer; John P A Ioannidis; Micheline Kirsch-Volders; Giuseppe Matullo; David H Phillips; Bernadette Schoket; Ulf Stromberg; Roel Vermeulen; Christopher Wild; Miquel Porta; Paolo Vineis
Journal:  PLoS Med       Date:  2011-10-25       Impact factor: 11.069

View more
  12 in total

1.  UEG Week 2020 Poster Presentations.

Authors: 
Journal:  United European Gastroenterol J       Date:  2020-10       Impact factor: 4.623

2.  Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease.

Authors:  Bonita Gu; Kavya Venkatesh; Astrid-Jane Williams; Watson Ng; Crispin Corte; Ali Gholamrezaei; Simon Ghaly; Wei Xuan; Sudarshan Paramsothy; Susan Connor
Journal:  World J Gastroenterol       Date:  2022-06-21       Impact factor: 5.374

3.  Illness Perceptions and Outcomes in Patients with Inflammatory Bowel Disease: Is Coping a Mediator?

Authors:  S J H van Erp; L K M P Brakenhoff; M Vollmann; D van der Heijde; R A Veenendaal; H H Fidder; D W Hommes; A A Kaptein; Andrea E van der Meulen-de Jong; M Scharloo
Journal:  Int J Behav Med       Date:  2017-04

4.  Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort.

Authors:  Sang Hyoung Park; Satimai Aniwan; W Scott Harmsen; William J Tremaine; Amy L Lightner; William A Faubion; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2019-05-04       Impact factor: 5.325

5.  Disability in Patients with Inflammatory Bowel Disease: Correlations with Quality of Life and Patient's Characteristics.

Authors:  Konstantinos Argyriou; Andreas Kapsoritakis; Konstantinos Oikonomou; Anastassios Manolakis; Eirini Tsakiridou; Spyridon Potamianos
Journal:  Can J Gastroenterol Hepatol       Date:  2017-05-29

6.  Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach.

Authors:  Silvio Danese; Rupa Banerjee; Jr Fraser Cummings; Iris Dotan; Paulo G Kotze; Rupert Wing Loong Leong; Kristine Paridaens; Laurent Peyrin-Biroulet; Glyn Scott; Gert Van Assche; Jan Wehkamp; Jesús K Yamamoto-Furusho
Journal:  Intest Res       Date:  2018-10-16

7.  "I can fight it!": A qualitative study of resilience in people with inflammatory bowel disease.

Authors:  Dan Luo; Zheng Lin; Xing-Chen Shang; Sha Li
Journal:  Int J Nurs Sci       Date:  2018-12-26

8.  Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.

Authors:  Brian G Feagan; Stefan Schreiber; Douglas C Wolf; Jeffrey L Axler; Arpeat Kaviya; Alexandra James; Rebecca I Curtis; Parnia Geransar; Andreas Stallmach; Robert Ehehalt; Bernd Bokemeyer; Javaria Mona Khalid; Sharon O'Byrne
Journal:  Inflamm Bowel Dis       Date:  2019-05-04       Impact factor: 5.325

9.  Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn's Disease: A Population-Based Cohort Study.

Authors:  Åsa H Everhov; Michael C Sachs; Jonas F Ludvigsson; Hamed Khalili; Johan Askling; Martin Neovius; Pär Myrelid; Jonas Halfvarson; Caroline Nordenvall; Jonas Söderling; Ola Olén
Journal:  Clin Epidemiol       Date:  2020-03-10       Impact factor: 4.790

10.  Real-world data about emotional stress, disability and need for social care in a German IBD patient cohort.

Authors:  Alica Kubesch; Patric Boulahrout; Natalie Filmann; Irina Blumenstein; Johannes Hausmann
Journal:  PLoS One       Date:  2020-01-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.